New York · Public charity
Alzheimer's Drug Discovery Foundation
Accelerate the discovery of drugs to prevent, treat and cure alzheimer's disease and related dementias.
- $31M
- Granted FY2025(still arriving)
- 23
- Itemized grants FY2025
- 26
- Organizations funded FY2024
- 58%
- First-time grantees FY2024
- Itemized, FY2025
- $16M
- The rest is grants the schedule does not break out
- Median grant, FY2025
- $353,147
- Largest grant, FY2025
- $4,995,519
- Organizations funded a year
- 15 to 34
- FY2018 to FY2024
- States reached, FY2025
- 15
- Total assets, FY2025
- $315M
How open it is to new grantees
In FY2024, 58% of the organizations Alzheimer's Drug Discovery Foundation funded were first-time grantees, receiving 65% of its grant dollars.
New vs renewed · share of each year
In FY2024, 35% of grant dollars renewed an existing relationship; $36M went to new ones.
RenewedFirst-time
Where new relationships form · theme of each grantee’s first grant
HealthEducationOther
How this is measured
First-time means a grantee’s first year in the filing window; renewed means funded in an earlier year too. The renewed share climbs naturally as a portfolio matures, so the signal is a year that bucks it (a wave of new grantees). The earliest year is left-censored: relationships that predate the data read as new. Theme is the grantee’s IRS cause.
The numbers by year
| Fiscal year | Organizations funded | To those organizations | First-time grantees |
|---|---|---|---|
| FY2025still arriving | 20 | $15M | 55% |
| FY2024 | 26 | $55M | 58% |
| FY2023 | 26 | $36M | 65% |
| FY2022 | 15 | $21M | 67% |
| FY2021 | 34 | $35M | 82% |
| FY2020 | 21 | $16M | 76% |
| FY2019 | 15 | $14M | 67% |
| FY2018 | 21 | $13M | 81% |
100% classified
What it funded, over time
Every grant placed by its stated purpose and the recipient’s mission, by year, FY2017 to 2024.
Health$208MEducation$600kRecreation & Sports$500kSocial Science$250kScience & Tech$135k
Where its grants go
Grant dollars by states, across the years we hold.
Which US states its grants reach
MN
IL
MI
NY
MA
NV
IA
IN
OH
PA
NJ
CT
RI
CA
UT
MO
KY
VA
MD
AZ
KS
TN
NC
DC
AL
GA
TX
Top grantees
Largest recipients by total granted, FY2017 to FY2025, and the share of each one’s budget the grants supplied at peak.
| Grantee | Total granted | Years | Share of their budget |
|---|---|---|---|
| Alamar Biosciences | $10,016,094 | 1 | n/a |
| C2N Diagnostics | $9,250,358 | 2 | n/a |
| Metro International Biotechedenroc | $8,000,000 | 2 | n/a |
| Therini Bio | $8,000,000 | 2 | n/a |
| Curasen Therapeutics Inc | $5,814,712 | 1 | n/a |
| Lifespan Extension Advocacy Foundation | $5,750,000 | 1 | n/a |
| Pharmatrophix | $5,609,700 | 1 | n/a |
| Coya Therapeutics | $5,000,000 | 1 | n/a |
| Davos Alzheimer's Collaborative Inc | $5,000,000 | 2 | 29% |
| Modulo Bio Inc | $4,845,794 | 1 | n/a |
Show all 127 grantees
| Grantee | Total granted | Years | Share of their budget |
|---|---|---|---|
| Alamar Biosciences | $10,016,094 | 1 | n/a |
| C2N Diagnostics | $9,250,358 | 2 | n/a |
| Metro International Biotechedenroc | $8,000,000 | 2 | n/a |
| Therini Bio | $8,000,000 | 2 | n/a |
| Curasen Therapeutics Inc | $5,814,712 | 1 | n/a |
| Lifespan Extension Advocacy Foundation | $5,750,000 | 1 | n/a |
| Pharmatrophix | $5,609,700 | 1 | n/a |
| Coya Therapeutics | $5,000,000 | 1 | n/a |
| Davos Alzheimer's Collaborative Inc | $5,000,000 | 2 | 29% |
| Modulo Bio Inc | $4,845,794 | 1 | n/a |
| Vaccinex Inc | $4,742,766 | 2 | n/a |
| Cognito Therapeutics | $4,556,150 | 1 | n/a |
| Aprinoia Therapeutics Inc | $4,357,900 | 1 | n/a |
| The Cleveland Clinic Foundation | $3,869,258 | 3 | 0% |
| Wake Forest University | $3,589,379 | 2 | 1% |
| Neuro Therapia Inc | $3,250,000 | 2 | n/a |
| Board of Regents Nevada System of Higher Education | $3,247,762 | 1 | n/a |
| Trustees of Boston University | $3,232,829 | 5 | 0% |
| Weill Medical College of Cornell Univers | $3,106,472 | 2 | n/a |
| Acurastem Incorporated | $3,092,453 | 2 | n/a |
| The Scripps Research Institute | $3,000,000 | 1 | 0% |
| Aquinnah Pharmaceuticals | $2,999,586 | 1 | n/a |
| Neurovision Imaging | $2,740,209 | 2 | n/a |
| Mms Holdings | $2,735,102 | 2 | n/a |
| Molecular Stethoscope Inc | $2,731,676 | 2 | n/a |
| Elysiun Health | $2,728,132 | 1 | n/a |
| Preventive Medicine Research Institute | $2,500,000 | 1 | 95% |
| Quanterix Corporation | $2,300,000 | 1 | n/a |
| Nerovision Imaging Inc | $2,200,950 | 1 | n/a |
| Cognition Therapeutics | $2,120,983 | 2 | n/a |
| University of California San Francisco | $2,106,911 | 3 | n/a |
| University of Arizona | $2,024,165 | 2 | n/a |
| Lexeo Theraputics LLC | $1,997,865 | 2 | n/a |
| Mti Biotech Inc | $1,958,576 | 3 | n/a |
| Alzpath Inc | $1,910,202 | 1 | n/a |
| Alzheimers Disease Data Initiative Inc | $1,881,800 | 1 | n/a |
| Biological Dynamics | $1,836,770 | 1 | n/a |
| Mindimmune Therapeutics | $1,835,000 | 1 | n/a |
| Neurokine Therapeutics | $1,688,985 | 2 | n/a |
| Washington University | $1,687,500 | 1 | 0% |
| Duke University | $1,631,197 | 2 | 0% |
| Foundation for the National Institutes of Health Inc | $1,548,432 | 5 | 1% |
| Gap Innovations Pbc | $1,500,000 | 1 | n/a |
| Linus Health | $1,487,860 | 2 | n/a |
| University of Kentucky Research Foundation | $1,434,160 | 1 | 0% |
| Viewmind | $1,429,119 | 1 | n/a |
| Johns Hopkins University | $1,387,825 | 5 | 0% |
| University of Rhode Island | $1,294,881 | 1 | n/a |
| Amprion | $1,202,350 | 2 | n/a |
| The Bluefield Project to Cure Frontotemporal Dementia | $1,200,000 | 1 | 36% |
| Wave Life Sciences | $1,190,392 | 1 | n/a |
| Eikonizo | $1,161,040 | 2 | n/a |
| Usagainstalzheimer's | $1,115,000 | 4 | 10% |
| Indiana University School of Medicine | $1,102,197 | 2 | n/a |
| Emory University | $1,059,849 | 4 | 0% |
| University of California Davis | $1,034,991 | 2 | n/a |
| Digital Cognition Tech | $1,001,853 | 1 | n/a |
| Astrocyte Pharmaceuticals Inc | $1,000,000 | 1 | n/a |
| Startup Health LLC | $975,875 | 1 | n/a |
| Mass General Brigham Incorporated | $963,533 | 1 | n/a |
| Amylyx Pharmaceuticals Inc | $928,234 | 1 | n/a |
| Cicardic LLC | $897,290 | 2 | n/a |
| The Ohio State University | $795,235 | 1 | n/a |
| Neurotrack Technologies | $792,990 | 1 | n/a |
| Esya Inc | $789,000 | 1 | n/a |
| Washington University | $780,328 | 2 | n/a |
| Neurodex | $750,000 | 1 | n/a |
| Clearview Healthcare Partners | $734,500 | 2 | n/a |
| Amprion | $725,750 | 2 | n/a |
| Imaginostics Inc | $725,274 | 1 | n/a |
| Icahn School of Medicine at Mount Sinai | $704,982 | 2 | 0% |
| Agenebio Inc | $649,704 | 2 | n/a |
| Cx Precision Medicine Inc | $633,961 | 1 | n/a |
| Life Biosciences | $630,460 | 1 | n/a |
| Vcuvcu Health Campus | $600,000 | 1 | n/a |
| Mass General Brigham Incorporated | $600,000 | 1 | n/a |
| University of Alabama at Birmingham | $600,000 | 1 | n/a |
| The University of Texas Southwestern Medical Cente | $600,000 | 1 | n/a |
| Tufts Medical Center Parent Inc | $599,788 | 1 | n/a |
| Albert Einstein College of Medicine Inc | $599,612 | 1 | n/a |
| The Board of Trustees of the University of Illinois | $599,515 | 1 | n/a |
| Case Western Reserve University | $599,259 | 1 | 0% |
| Children's Hospital Corporation | $572,678 | 1 | 0% |
| University of Utah | $500,000 | 1 | n/a |
| Emtherapro | $499,415 | 1 | n/a |
| Altoida | $498,335 | 1 | n/a |
| University of Minnesota | $493,875 | 1 | n/a |
| Diamir Biosciences | $492,000 | 1 | n/a |
| Brainscope Company Inc | $491,086 | 1 | n/a |
| Beth Israel Deaconess Medical Center Inc | $349,590 | 1 | 0% |
| Gatehouse Bio Inc | $349,000 | 1 | n/a |
| University of Massachusetts | $342,429 | 1 | n/a |
| The Rockefeller University | $320,000 | 1 | 0% |
| Hebrew Rehabilitation Center | $319,609 | 1 | 0% |
| Rio Pharmaceuticals Inc | $308,869 | 1 | n/a |
| University of California Santa Barbara | $300,000 | 1 | n/a |
| University of California Berkeley Foundation | $300,000 | 1 | 0% |
| Caspian Therapeutics | $295,000 | 1 | n/a |
| Usf Research Foundation Inc | $263,649 | 1 | 2% |
| C Light Technologies | $251,021 | 1 | n/a |
| Circular Genomics Inc | $250,000 | 1 | n/a |
| Banner Health | $250,000 | 1 | n/a |
| Northeastern University | $250,000 | 1 | 0% |
| University of Kansas Medical Center | $250,000 | 1 | n/a |
| Sunbird Bio Inc | $249,887 | 1 | n/a |
| Neuroage Therapeutics | $249,817 | 1 | n/a |
| Gliacure Inc | $243,595 | 1 | n/a |
| Pelagos Pharmaceuticals | $214,118 | 1 | n/a |
| Digital Medicine Society Inc | $210,000 | 1 | 3% |
| Mass General Brigham Incorporated | $206,836 | 1 | n/a |
| Cogentis Therapeutics | $188,193 | 1 | n/a |
| Regents of the University of California at Irvine | $175,000 | 1 | n/a |
| Vanderbilt University | $150,000 | 1 | 0% |
| The J David Gladstone Institutes | $150,000 | 1 | 0% |
| Plico Biotech | $148,000 | 1 | n/a |
| Cornell University | $135,000 | 1 | 0% |
| The Mount Sinai Hospital | $100,000 | 1 | 0% |
| The Milken Institute | $100,000 | 2 | 0% |
| Biotechnology Innovation Organization | $73,700 | 1 | 0% |
| Global Alzheimer's Platform Foundation Inc | $50,000 | 2 | 0% |
| Als Biopharma | $30,000 | 1 | n/a |
| Neurolucent | $30,000 | 1 | n/a |
| Intra-Cellular Therapies | $10,983 | 1 | n/a |
| The American Neurological Association | $10,000 | 1 | 0% |
| The Association for Frontotemporal Degeneration | $10,000 | 1 | 0% |
| Lewy Body Dementia Association Inc | $10,000 | 1 | 0% |
| Mobility Consulting Group LLC | $9,992 | 1 | n/a |
Plus 15 recipients with no EIN on record ($18M), not named here.
Where it is load-bearing
Alzheimer's Drug Discovery Foundation supplied at least a quarter of the budget for 3 of its grantees at some point. The chart plots its 34 largest grantees; load-bearing ones sit top left.
Tap a dot to name the grantee.
How this is measured
Share of budget is the funder’s grant in a year over the grantee’s total revenue that year, at its highest across the years we hold; revenue is from all sources. Only grantees confirmed against their own filings, whose grants do not exceed their revenue, are plotted: the largest 34.
Co-funders
Grantmakers whose grantees overlap with this funder’s far more than size alone predicts. Closer means stronger alignment; arcs show where they also fund each other. Here they form a tightly interlocked group: most of these funders back each other's grantees too.
Alzheimer's Disease & Related Disorders Association IncIL32.2× affinity13 shared granteesties to 11 of 11Hover any node to trace its alignments.Compare side by side →
Open a dossier: Alzheimer's Disease & Related Disorders Association Inc · The Michael J Fox Foundation for Parkinson's Research · Amyotrophic Lateral Sclerosis Assn · Beth Israel Deaconess Medical Center Inc · Mayo Clinic · President and Fellows of Harvard College · Yale University · The Trustees of Columbia University in the City of New York · American Heart Association Inc · Marin Community Foundation · National Philanthropic Trust · American Endowment Foundation
How this is measured
Affinity is a Gamma-Poisson posterior co-funding rate, re-centered on the typical rate, so thin evidence shrinks toward no signal. Overlap is association, not proof of shared intent.
Compare Alzheimer's Drug Discovery Foundation with peer funders
About Alzheimer's Drug Discovery Foundation
- How much does Alzheimer's Drug Discovery Foundation give?
- Alzheimer's Drug Discovery Foundation reported 23 itemized grants totaling $16,077,916, out of $30,837,976 in total grant expense reported on the return in its FY2025 IRS filing. It funded between 15 and 34 organizations a year over FY2018 to FY2024.
- What does Alzheimer's Drug Discovery Foundation fund?
- By grant dollars over FY2017 to FY2025, its largest causes are Health (99%), Education (0%), Recreation & Sports (0%).
- Who are Alzheimer's Drug Discovery Foundation's largest grantees?
- By total granted over FY2017 to FY2025: Alamar Biosciences ($10M), C2N Diagnostics ($9.3M), Metro International Biotechedenroc ($8.0M).
- Does Alzheimer's Drug Discovery Foundation fund new organizations?
- In FY2024, 58% of the organizations it funded were first-time grantees.
- Which funders back the same organizations as Alzheimer's Drug Discovery Foundation?
- Its strongest co-funders, measured against what their size predicts, include Alzheimer's Disease & Related Disorders Association Inc, The Michael J Fox Foundation for Parkinson's Research, Amyotrophic Lateral Sclerosis Assn.
- Where is Alzheimer's Drug Discovery Foundation based?
- Alzheimer's Drug Discovery Foundation is based in NY.
Play a game based on Alzheimer's Drug Discovery’s filings →
More from the funding graph
The unnamed billions
grants reported with no recipient in the public record
The regranting layer
51% of grant dollars land in the regranting layer
The DAF merry-go-round
$9.7B circulates between donor-advised funds
The endowment market
who holds foundation money, and what just moved
The camps
funders cluster by geography, not ideology
By state
where grant money is based, and what stays home